Health First will unveil and officially open to the public its new Sleep Center in Melbourne on Sunday, February 16.

Primary aldosteronism treatment response was associated with higher plasma renin activity and serum potassium levels and lower aldosterone.

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years and older. One capsule of ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Women with hypertension who followed a very low-calorie ketogenic diet had greater reductions in systolic and diastolic blood ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILS ...

OMNIS, the modular platform for chemical analysis from Metrohm has become ever more powerful. With the launch of the OMNIS ...

This study presents efficient CaO/ZnO composite catalysts for biodiesel production from soybean oil, achieving 99% conversion ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...

The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...

When using high-flow nasal cannula (HFNC), setting a higher flow rate of 60 vs 40 L/min for post-extubation care did not improve key outcomes.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.